RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/17409436http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/17409436http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/17409436http://www.w3.org/2000/01/rdf-schema#comment"To disclose the molecular mechanism of bladder cancer, the second most common genitourinary tumor, we had previously done genome-wide expression profile analysis of 26 bladder cancers by means of cDNA microarray representing 27,648 genes. Among genes that were significantly up-regulated in the majority of bladder cancers, we here report identification of M-phase phosphoprotein 1 (MPHOSPH1) as a candidate molecule for drug development for bladder cancer. Northern blot analyses using mRNAs of normal human organs and cancer cell lines indicated this molecule to be a novel cancer-testis antigen. Introduction of MPHOSPH1 into NIH3T3 cells significantly enhanced cell growth at in vitro and in vivo conditions. We subsequently found an interaction between MPHOSPH1 and protein regulator of cytokinesis 1 (PRC1), which was also up-regulated in bladder cancer cells. Immunocytochemical analysis revealed colocalization of endogenous MPHOSPH1 and PRC1 proteins in bladder cancer cells. Interestingly, knockdown of either MPHOSPH1 or PRC1 expression with specific small interfering RNAs caused a significant increase of multinuclear cells and subsequent cell death of bladder cancer cells. Our results imply that the MPHOSPH1/PRC1 complex is likely to play a crucial role in bladder carcinogenesis and that inhibition of the MPHOSPH1/PRC1 expression or their interaction should be novel therapeutic targets for bladder cancers."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.org/dc/terms/identifier"doi:10.1158/0008-5472.can-06-3748"xsd:string
http://purl.uniprot.org/citations/17409436http://purl.org/dc/terms/identifier"doi:10.1158/0008-5472.can-06-3748"xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Miki T."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Miki T."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Nakamura Y."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Nakamura Y."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Fujioka T."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Fujioka T."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Shuin T."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Shuin T."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Katagiri T."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Katagiri T."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Takata R."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Takata R."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Shimo A."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Shimo A."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Kanehira M."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/author"Kanehira M."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/date"2007"xsd:gYear
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/date"2007"xsd:gYear
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/name"Cancer Res."xsd:string
http://purl.uniprot.org/citations/17409436http://purl.uniprot.org/core/name"Cancer Res."xsd:string